A phase II clinical trial studied lapatinib in 18 patients with advanced progressing chordoma, with the expression and activation of EGFR evaluated by immunohistochemistry and/or phosphoarrays, reporting six PR (33.3%) and seven SD (38.9%) according to the Choi criteria, with a median PFS of 6 months [90]. This evidence concerns the gene EGFR and chordoma.